Payment overview · 2025
General Payments
$466.92
19 reported records · 11 companies
Healthcare provider profile · identity verified
Igor Gary Shlifer, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · WOODLAND HILLS, CA · NPI 1295174860
Verified facts
What the public records show
CMS Open Payments records show Igor Gary Shlifer, D.O. received $466.92 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 611 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $128.02 | 27.4% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $80.87 | 17.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.50 | 13.8% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $40.45 | 8.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.85 | 5.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.99 | 5.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.58 | 5.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $21.48 | 4.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.27 | 4.3% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $18.33 | 3.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.58 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $466.92 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $128.02 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $80.87 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.50 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $40.45 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 56 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
137 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
611 | 95 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1453 | 269 |
| Levothyroxine Sodium | Levothyroxine Sodium | 940 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 877 | 190 |
| Pantoprazole Sodium | Pantoprazole Sodium | 763 | 150 |
| Metformin Hcl | Metformin Hcl | 702 | 141 |
| Eliquis | Apixaban | 611 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 604 | 121 |
| Losartan Potassium | Losartan Potassium | 600 | 115 |
| Furosemide | Furosemide | 591 | 132 |
| Gabapentin | Gabapentin | 565 | 118 |
| Quetiapine Fumarate | Quetiapine Fumarate | 511 | 104 |
| Trazodone Hcl | Trazodone Hcl | 480 | 104 |
| Escitalopram Oxalate | Escitalopram Oxalate | 390 | 74 |
| Famotidine | Famotidine | 379 | 77 |
| Finasteride | Finasteride | 361 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 358 | 71 |
| Donepezil Hcl | Donepezil Hcl | 356 | 69 |
| Lisinopril | Lisinopril | 346 | 73 |
| Omeprazole | Omeprazole | 337 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 67 |
| Potassium Chloride | Potassium Chloride | 296 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 273 | 52 |
| Carvedilol | Carvedilol | 270 | 50 |
| Mirtazapine | Mirtazapine | 270 | 51 |
| Memantine Hcl | Memantine Hcl | 238 | 46 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 213 | 41 |
| Xarelto | Rivaroxaban | 197 | 27 |
| Allopurinol | Allopurinol | 188 | 33 |
| Risperidone | Risperidone | 188 | 38 |
| Simvastatin | Simvastatin | 179 | 36 |
| Latanoprost | Latanoprost | 178 | 45 |
| Divalproex Sodium | Divalproex Sodium | 177 | 29 |
| Sertraline Hcl | Sertraline Hcl | 163 | 27 |
| Ciclopirox | Ciclopirox Olamine | 157 | 69 |
| Lorazepam | Lorazepam | 155 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 56 |
| Jardiance | Empagliflozin | 145 | 30 |
| Atenolol | Atenolol | 143 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 27 |
| Creon | Lipase/Protease/Amylase | 137 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 37 |
| Levetiracetam | Levetiracetam | 132 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 127 | 83 |
| Ketoconazole | Ketoconazole | 125 | 30 |
| Januvia | Sitagliptin Phosphate | 119 | 17 |
| Olanzapine | Olanzapine | 119 | 26 |
| Montelukast Sodium | Montelukast Sodium | 112 | 21 |
| Spironolactone | Spironolactone | 111 | 30 |
| Alendronate Sodium | Alendronate Sodium | 110 | 22 |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 109 | 17 |
| Ezetimibe | Ezetimibe | 107 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 106 | 17 |
| Diclofenac Potassium | Diclofenac Potassium | 103 | 22 |
| Valsartan | Valsartan | 101 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 27 |
| Nifedipine Er | Nifedipine | 97 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 29 |
| Dexlansoprazole Dr | Dexlansoprazole | 93 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 31 |
| Glipizide | Glipizide | 89 | 22 |
| Ibuprofen | Ibuprofen | 79 | 23 |
| Bupropion Xl | Bupropion Hcl | 78 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 78 | 17 |
| Tramadol Hcl | Tramadol Hcl | 75 | 36 |
| Vascepa | Icosapent Ethyl | 75 | 13 |
| Aripiprazole | Aripiprazole | 71 | 12 |
| Azithromycin | Azithromycin | 71 | 61 |
| Benazepril Hcl | Benazepril Hcl | 71 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 20 |
| Meloxicam | Meloxicam | 70 | 20 |
| Baclofen | Baclofen | 65 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | 21 |
| Meclizine Hcl | Meclizine Hcl | 62 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 12 |
| Bumetanide | Bumetanide | 60 | 15 |
| Levofloxacin | Levofloxacin | 60 | 47 |
| Ondansetron Odt | Ondansetron | 59 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 12 |
| Myrbetriq | Mirabegron | 58 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Entresto | Sacubitril/Valsartan | 56 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 13 |
| Memantine Hcl Er | Memantine Hcl | 55 | 11 |
| Midodrine Hcl | Midodrine Hcl | 55 | 11 |
| Clonidine Hcl | Clonidine Hcl | 54 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Nystatin | Nystatin | 53 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 51 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 13 |
| Irbesartan | Irbesartan | 51 | suppressed |
| Pregabalin | Pregabalin | 50 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 42 |
| Prednisone | Prednisone | 49 | 30 |
| Sucralfate | Sucralfate | 49 | suppressed |
| Lamotrigine | Lamotrigine | 48 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Glipizide Er | Glipizide | 47 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 47 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 27 |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 45 | suppressed |
| Fentanyl | Fentanyl | 44 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 44 | suppressed |
| Ozempic | Semaglutide | 44 | 15 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 41 | 11 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Timolol Maleate | Timolol Maleate | 40 | 12 |
| Valacyclovir | Valacyclovir Hcl | 40 | 12 |
| Alprazolam | Alprazolam | 39 | 13 |
| Anastrozole | Anastrozole | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 12 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Loperamide | Loperamide Hcl | 38 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 37 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 18 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 12 |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 31 | 18 |
| Linzess | Linaclotide | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | 12 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | 11 |
| Folic Acid | Folic Acid | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Erythromycin | Erythromycin Base | 26 | 20 |
| Metformin Er Gastric | Metformin Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 15 |
| Lumigan | Bimatoprost | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Austedo Xr | Deutetrabenazine | 20 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 16 | suppressed |
| Galantamine Er | Galantamine Hbr | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Brinzolamide | Brinzolamide | 11 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $466.92 · 19 records | ABBVIE INC. | ABILIFY MAINTENA, ARISTADA, CAPLYTA, CRYSVITA, ENTRESTO, ImmunoCAP, KISUNLA, LEQVIO, LYBALVI, PAXLOVID, REXULTI, VRAYLAR, YUPELRI | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error